VIDEO: Tonix CEO discusses sublingual treatment for patients with fibromyalgia

SAN FRANCISCO — Seth Lederman, MD, CEO of Tonix Pharmaceuticals, discusses phase 2b trial results with 200 patients with fibromyalgia who received placebo or TNX-102 SL, a sublingual, low-dose form of cyclobenzaprine designed for nighttime use.

Three abstracts related to the study at the American College of Rheumatology Annual Meeting, and Lederman said a phase 3 trial with TNX-102 SL is underway with patinets with fibromyalgia.